Optimize Your Health - Available Everywhere in the US

  188-8981-6784    HIPAA Compliant  ·  Licensed U.S. Providers

CJC-1295 / Ipamorelin

CJC-1295 + Ipamorelin — Dual-Pathway GH Stimulation Protocol. Physician-Supervised

The CJC-1295 and ipamorelin combination is one of the most widely used GH peptide protocols in physician-supervised men’s health. By activating two different receptor pathways simultaneously — GHRH receptor and ghrelin receptor — research has investigated whether this dual stimulation produces GH release that exceeds what either compound achieves independently. It is available at OptiMale USA following baseline bloodwork and clinical assessment.

WHAT IS IT?

Understanding CJC-1295 / Ipamorelin

Growth hormone release from the pituitary is governed by two main signals: GHRH (growth hormone-releasing hormone), which primes the pituitary to release GH, and ghrelin, which triggers the actual GH pulse. CJC-1295 mimics GHRH — occupying and activating GHRH receptors to prime the pituitary. Ipamorelin mimics ghrelin — activating the GHSR (ghrelin receptor) to trigger GH secretion. Used together, they act on both arms of this system simultaneously.
Research has investigated this dual-pathway approach for producing amplified GH pulse amplitude and frequency compared to either compound alone. The combination is typically administered as a single subcutaneous injection before bed to align with the body’s natural GH release during deep sleep. At OptiMale USA, this combination is assessed individually — baseline IGF-1 testing is required, and dosing is adjusted based on your IGF-1 response throughout the protocol.

Quick Facts

Injection

Timeline: Sleep and recovery improvements in 1-3 weeks; body composition changes at 8-12 weeks
Lab required: Yes
Ongoing maintenance: Yes — cycling protocols and periodic lab monitoring
Pricing:  Contact for Pricing

Related Treatments

Benefits

Two receptor pathways addressed simultaneously

GHRH receptor (CJC-1295) and ghrelin receptor (ipamorelin) are the two primary drivers of pituitary GH release. Research has investigated the combination for producing GH pulse amplitude and frequency beyond what single-pathway stimulation achieves.

Ipamorelin's selective hormonal profile

Ipamorelin does not significantly stimulate cortisol or prolactin — a selectivity that research has characterised as an advantage over older GHRP compounds. This means the combination targets GH release specifically without broad off-target hormonal effects.

Physiological pulsatile release

The combination uses CJC-1295 without DAC in most protocols, preserving the natural pulsatile pattern of GH secretion rather than producing constant elevation. Research has examined pulsatile GH release as more physiologically appropriate than sustained elevation.

Recovery, lean mass, and sleep research

GH and downstream IGF-1 are involved in protein synthesis, satellite cell activity, and tissue repair. Research has studied this combination's effects on GH and IGF-1 levels, sleep quality, and body composition markers in men with age-related GH decline.

Who Is This For?

Am I a Good Candidate?

Ideal For

  • Men over 30 with documented low GH or IGF-1 levels through bloodwork
  • Men experiencing age-related changes in recovery, sleep, body composition, or energy
  • Men on TRT or other hormone programs who want to add physician-supervised GH support
  • Men who want a well-researched combination approach rather than single-agent GH stimulation

Not Recommended If

  • Men with active malignancy
  • Men with pituitary disorders or significantly elevated baseline IGF-1
  • Men under 25 or with open growth plates
  • Men who have not had baseline IGF-1 testing prior to beginning a GH peptide protocol
Safety

Potential Side Effects

The combination is generally well tolerated. Side effects reflect those of both individual compounds and are typically mild. IGF-1 monitoring is essential throughout all GH peptide protocols at OptiMale USA.

Common Questions

Frequently Asked Questions

Get started

Discuss CJC-1295 + Ipamorelin With a Provider

Your free consultation is the first step. A licensed OptiMale USA provider will review your bloodwork, health history, and goals before making any recommendations.

cjc-1295-ipamorelin

These statements have not been evaluated by the Food and Drug Administration. The information on this website is provided for educational and informational purposes only and does not constitute medical advice, a diagnosis, a treatment recommendation, or an offer to prescribe, supply, compound, administer, or dispense any product.

Compounded medications. Compounded medications, including compounded semaglutide and compounded tirzepatide, are not FDA-approved and are not generic equivalents of brand-name products such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. The FDA does not review compounded drugs for safety, effectiveness, or quality prior to dispensing. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities pursuant to a valid prescription from a licensed provider following individual patient evaluation. Availability of compounded medications varies by state and is subject to applicable state and federal law.

Research compounds. Certain compounds referenced on this website are research compounds that are not approved by the FDA for human use and have not been evaluated by the FDA for safety, efficacy, or quality. Information about these compounds is provided solely for educational and informational purposes and reflects publicly available scientific literature. OptiMale USA and its affiliated providers do not prescribe, supply, recommend, compound, administer, or dispense research compounds, and nothing on this website should be construed as an offer to do so. Patient consent forms purporting to waive provider duty of care with respect to research compounds are not recognized as a defense to professional liability and are not used by OptiMale USA.

Clinical services. All prescription products and services offered through OptiMale USA are prescribed exclusively by board-certified, licensed U.S. providers following individual clinical evaluation, comprehensive bloodwork where indicated, and a detailed health assessment. Available services and products vary by state based on provider licensure and applicable law. No provider-patient relationship is established by use of this website; a provider-patient relationship is formed only upon completion of a clinical evaluation with a licensed OptiMale USA provider.

Individual results vary. Always consult a qualified healthcare provider before beginning any new health protocol.

  • Home
  • Products
  • Solutions
  • How it Works
  • Peptide Library